October 2018, Melbourne:Medical diagnostics company Rhythm Biosciences Limited (ASX: RHY) has successfully completed the next phase of its key reagent development program: the identification of antibodies crucial to developing its lead colorectal cancer blood test ColoSTAT®.
ColoSTAT® is designed to be a simple, cost-effective, accurate blood test suitable for mass population screening of the world’s third most common cancer
